MG
VINC

Michael Gelband’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Michael Gelband’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,101
Closed -$388K – 2182
2024
Q3 		$388K Buy
27,101
+3,203
+13% +$43.9K ﹤0.01% 1284
2024
Q2 		$387K Buy
23,898
+8,066
+51% +$202K ﹤0.01% 1269
2024
Q1 		$1.6M Sell
15,832
-374
-2% -$23.6K 0.01% 793
2023
Q4 		$382K Sell
16,206
-3,270
-17% -$55K ﹤0.01% 1109
2023
Q3 		$393K Sell
19,476
-1,848
-9% -$35.8K ﹤0.01% 1322
2023
Q2 		$554K Buy
21,324
+1,737
+9% +$49.7K ﹤0.01% 1319
2023
Q1 		$407K Buy
19,587
+7,037
+56% +$158K ﹤0.01% 1391
2022
Q4 		$256K Buy
12,550
+3,935
+46% +$74.1K ﹤0.01% 1401
2022
Q3 		$238K Buy
8,615
+3,610
+72% +$104K ﹤0.01% 1590
2022
Q2 		$132K Buy
+5,005
New +$223K ﹤0.01% 1715
2021
Q2 		– Sell
-892
Closed -$344K – 2912
2021
Q1 		$344K Buy
+892
New +$360K 0.01% 1579

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's VINC Position: Q4 2024 in Review

Michael Gelband sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 27,101 shares — an estimated $388K sold.

Michael Gelband first reported a position in VINC in Q1 2021 and held it in 11 quarters. The position peaked at $1.6M in Q1 2024. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

  • Michael Gelband reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Michael Gelband sold 27,101 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $388K.
  • Michael Gelband first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Michael Gelband's Vincerx Pharma, Inc. Common Stock position peaked at $1.6M in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.